FDA Classifies Fancy Blood Cancer Gene Test
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting a special kind of test that spots chromosome problems in blood cancer patients into a safer, more controlled category called Class II. This change helps make sure the test works well and is safe, while also making it easier for new and helpful devices to reach patients faster. Labs and device makers should get ready for these new rules, which aim to speed up access without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FISH Chromosome Test Moved to Class II
The FDA is officially classifying the fluorescence in situ hybridization (FISH) test that detects chromosomal abnormalities in patients with hematologic malignancies as Class II (special controls). The Agency says this classification provides reasonable assurance of the test's safety and effectiveness and is intended to enhance patient access to these devices while reducing regulatory burdens and speeding access without extra costs.
Labs and Makers Face Lower Regulatory Burden
The FDA says reclassifying this FISH-based chromosomal abnormality test into Class II (special controls) reduces regulatory burdens for labs and device makers and should make it easier for new devices to reach patients faster. The rule tells labs and device makers to prepare for the new classification and frames the change as speeding access without extra costs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in